Role of pharmacoeconomic analysis in R&D decision making Paul Miller Leading Article 17 September 2012 Pages: 1 - 12
Pharmacoeconomic impact of non-compliance with statins Andrew M. PetersonWilliam F. McGhan Review Article 17 September 2012 Pages: 13 - 25
A review of the costs of managing childhood epilepsy Ettore BeghiBarbara FrigeniLivio Garattini Review Article 17 September 2012 Pages: 27 - 45
Measuring productivity changes in economic evaluation Marc KoopmanschapAlex BurdorfHans Severens Practical Application 17 September 2012 Pages: 47 - 54
Household-based costs and benefits of vaccinating healthy children in daycare against influenza virus Maria PisuMartin I. MeltzerMichael Haber Original Research Article 17 September 2012 Pages: 55 - 67
Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer Davide RadiceAlberto Redaelli Original Research Article 17 September 2012 Pages: 69 - 75
A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting Anthony H. HarrisElena GospodarevskayaAlison J. Ritter Original Research Article 17 September 2012 Pages: 77 - 91
Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder Kristina SecnikAndrine SwensenMaureen J. Lage Original Research Article 17 September 2012 Pages: 93 - 102